Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

Published:2020-01-20 Issue:2 Volume:1 Page:176-183
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Moding Everett J.^ORCID,Liu Yufei,Nabet Barzin Y.^ORCID,Chabon Jacob J.,Chaudhuri Aadel A.^ORCID,Hui Angela B.,Bonilla Rene F.,Ko Ryan B.^ORCID,Yoo Christopher H.^ORCID,Gojenola Linda,Jones Carol D.,He Jianzhong,Qiao Yawei,Xu Ting,Heymach John V.,Tsao Anne,Liao Zhongxing,Gomez Daniel R.,Das Millie,Padda Sukhmani K.,Ramchandran Kavitha J.,Neal Joel W.,Wakelee Heather A.,Loo Billy W.^ORCID,Lin Steven H.^ORCID,Alizadeh Ash A.^ORCID,Diehn Maximilian^ORCID

Funder

Radiological Society of North America

American Society for Radiation Oncology Stanford Radiation Oncology Kaplan Fellowship

Virginia and D.K. Ludwig Fund for Cancer Research

U.S. Department of Health & Human Services | NIH | National Cancer Institute

CRK Faculty Scholar Fund

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s43018-019-0011-0.pdf

Reference27 articles.

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

2. Ettinger, D. S. et al. Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 15, 504–535 (2017).

3. Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J. Thorac. Oncol. 11, 39–51 (2016).

4. Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342–2350 (2018).

5. Bradley, J. D. et al. Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy ± cetuximab for stage III NSCLC. Int. J. Radiat. Oncol. Biol. Phys. 99, S105 (2017).

Cited by 231 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer?;The Journal of Liquid Biopsy;2024-12

2. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review;International Immunopharmacology;2024-11

3. Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer;Translational Research;2024-10

4. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-09

5. Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer;Radiotherapy and Oncology;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3